Cerity Partners’s Heron Therapeutics HRTX Stock Holding History

Cerity Partners’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.8K	Buy	60,341 +43,098	+250%	+$34.6K	﹤0.01%	3352
2026 Q1	$13.8K	Buy	17,243 +180	+1%	+$209	﹤0.01%	3196
2025 Q4	$22.2K	Sell	17,063 -34,649	-67%	-$42.8K	﹤0.01%	2841
2025 Q3	$65.2K	Buy	+51,712	New	+$82K	﹤0.01%	2668
2024 Q4	–	Sell	-10,348	Closed	-$20.6K	–	2505
2024 Q3	$20.6K	Buy	+10,348	New	+$24.7K	﹤0.01%	2512
2020 Q4	–	Sell	-35,600	Closed	-$528K	–	649
2020 Q3	$528K	Sell	35,600 -2,438	-6%	-$38K	0.02%	315
2020 Q2	$560K	Buy	38,038 +2,438	+7%	+$40.1K	0.03%	267
2020 Q1	$418K	Sell	35,600 -850	-2%	-$16K	0.03%	303
2019 Q4	$857K	Buy	36,450 +1,370	+4%	+$30.3K	0.04%	259
2019 Q3	$649K	Buy	35,080 +10,080	+40%	+$186K	0.04%	284
2019 Q2	$465K	Sell	25,000 -90	-0.4%	-$1.8K	0.03%	330
2019 Q1	$613K	Buy	+25,090	New	+$657K	0.04%	301

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Cerity Partners's HRTX Position: Q2 2026 in Review

Cerity Partners increased its Heron Therapeutics (HRTX) stake by 250% in Q2 2026, buying an estimated $34.6K and bringing the position to 60,341 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3352.

Cerity Partners first reported a position in HRTX in Q1 2019 and has held it in 12 quarters since. The position peaked at $857K in Q4 2019. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

Cerity Partners held 60,341 shares of Heron Therapeutics worth $25.8K as of Q2 2026.
Cerity Partners bought 43,098 Heron Therapeutics shares in Q2 2026, an estimated $34.6K.
Heron Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3352 holding.
Cerity Partners first reported a position in Heron Therapeutics in Q1 2019 and has held it in 12 quarters since.
Cerity Partners's Heron Therapeutics position peaked at $857K in Q4 2019.
163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.